• Beyond Potency: Translational Strategy for (+)-JQ1

  2026-09-03

  A mechanistic and strategic guide to using (+)-JQ1 as a BET bromodomain inhibitor across cancer, apoptosis, inflammation, and BRDT-focused reproductive biology, with emphasis on response kinetics, assay design, and translational boundaries.

• Troglitazone (A3893) Assay Reliability Guide

  2026-09-03

  A scenario-based guide to using Troglitazone (SKU A3893) in cell viability, proliferation, and cytotoxicity workflows. It addresses solvent compatibility, assay optimization, interpretation of PPAR-driven effects, oncology translation, and practical product-selection criteria.

• Tobramycin Workflows for Resistance Research

  2026-09-02

  Build reproducible aqueous microdilution assays with Tobramycin for Gram-negative susceptibility testing, resistance profiling, and bacterial protein synthesis studies. This guide combines product-specific handling with the comparative, inoculum-aware design used in a 565-isolate aminoglycoside study.

• BIBR 1532: Reliable Telomerase Assay Workflows

  2026-09-02

  This scenario-based guide shows how BIBR 1532, SKU A1945, can improve interpretation of telomerase inhibition, cancer cell proliferation, and apoptosis assays. It covers dosing logic, solvent compatibility, orthogonal readouts, comparison with CF10–EdU telomere damage, and practical supplier selection.

• Pomalidomide (CC-4047) for Myeloma Research

  2026-09-01

  Build genotype-aware multiple myeloma experiments around Pomalidomide (CC-4047), combining tumor-cell, cytokine, and erythroid readouts instead of relying on viability alone. This workflow uses molecularly diverse cell-line panels, solvent controls, and practical troubleshooting to distinguish tumor microenvironment modulation from assay artifacts.

• HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody Workflow

  2026-09-01

  Translate goat-primary immunostaining into a consistent fluorescence workflow for hypoxia, inflammation, and tissue-injury studies. This Alexa Fluor 488 conjugated secondary antibody supports ICC/IF, IHC, Western blotting, flow cytometry, and ELISA while offering practical signal amplification and flexible assay transfer.

• SERCA2–CaN–FoxO1–FABP4 in Atherosclerosis

  2026-08-31

  The 2025 reference study identifies a mechanistic connection between SERCA2 dysfunction, calcineurin/FoxO1 signaling, FABP4 transcription, and macrophage foam cell formation. Its combination of a SERCA2 C674S knock-in model, serum metabolomics, macrophage assays, and pharmacological or genetic pathway intervention supports FABP4 as a tractable downstream target in atherosclerosis research.

• Mitoxantrone HCl: Assays, Workflows, and Insights

  2026-08-31

  Mitoxantrone HCl supports DNA-damage, apoptosis, viability, immune-cell, and estrogen-receptor studies in one adaptable research workflow. Its newly described ERα interface activity adds a resistance-focused assay strategy beyond conventional topoisomerase II readouts.

• CLCC1 and Herpesvirus Nuclear Egress

  2026-08-30

  A whole-genome CRISPR screen identified CLCC1 as an essential host factor for the membrane-fusion step of herpesvirus nuclear egress. The study links CLCC1 loss to perinuclear capsid accumulation, impaired nuclear pore insertion, and reduced viral production, providing a framework for investigating an evolutionarily conserved membrane-remodeling process.

• RSV NS3 Hijacks Kinase Signaling for Co-survival

  2026-08-29

  Zhuang et al. show that Rice stripe virus NS3 temporally redirects the OsSnRK3.25–OsCBL1/3–OsRBOHF pathway, balancing antiviral RNA interference, reactive oxygen species, programmed cell death, and transmission. The study provides a mechanistic model in which phosphorylation and host-pathway hijacking allow RSV to modulate disease severity across rice, planthopper, and related host systems.

• Troglitazone: PPARγ Agonist Research Workflows

  2026-08-28

  Troglitazone provides a practical way to perturb PPARγ-centered lipid and glucose metabolism in diabetes, cancer, and macrophage assays. This guide translates its documented properties into reproducible workflows while separating established product facts from exploratory SPP1/TAM research hypotheses.

• PPARγ, Macrophage Polarization, and DSS-Induced IBD

  2026-08-28

  The reference study links PPARγ activation with a shift from proinflammatory M1 toward reparative M2 macrophage features in cellular and DSS-induced murine inflammatory bowel disease models. Its central contribution is the integration of macrophage phenotype, STAT-1/STAT-6 signaling, intestinal barrier integrity, and clinical disease outcomes into one mechanistic framework.

• Fulvestrant (ICI 182,780): Mechanism & Uses

  2026-08-27

  Fulvestrant, also called ICI 182,780, is an estrogen receptor antagonist that promotes ERα degradation and suppresses ER-mediated signaling. Its research value includes MDM2 protein degradation, apoptosis induction in breast cancer cells, and controlled modeling of endocrine therapy resistance.

• Rice Stripe Virus NS3 and Host Kinase Signaling

  2026-08-27

  A 2025 Developmental Cell study shows that Rice stripe virus NS3 dynamically exploits the OsSnRK3.25–OsCBL1/3–OsRBOHF pathway to balance pathogenicity, host defense, and transmission. Its stage-dependent phosphorylation model provides a useful framework for interpreting virus–plant–vector co-survival and for designing pathway-focused experiments.

• Lenalidomide (CC-5013) in Myeloma Assays

  2026-08-26

  Use Lenalidomide (CC-5013) to connect antimyeloma activity with immune restoration, angiogenesis control, and innate immune reprogramming. This workflow-oriented guide shows how to build combination assays around DOT1L inhibition while avoiding common dosing, solubility, and interpretation errors.

8385 records 1/559 page Next 12345 下5页 Last page